Hebrew University researchers seek to 'inactivate' cancer cells

August 07, 2001

Jerusalem, August 7, 2001 - Controlling cancer by inducing it to remain in a dormant state -- rather than trying to achieve massive killing of cancer cells through conventional chemotherapy -- offers a new and safer approach to battling this disease, say researchers at the Lautenberg Center for General and Tumor Immunology of the Hebrew University-Hadassah Medical School.

The advantage of this approach is that it holds out the possibility of treatment that would be much less harmful than regular chemotherapy, which involves large doses of toxic drugs that inevitably destroy normal cells as well as cancer cells.

Eitan Yefenof, the Bertha and Max Densen Professor of General and Tumor Immunology, and his associates at the Lautenberg Center have developed a technique of linking a toxic molecule with an antibody directed against specific cancer cell receptors. By introducing this material into the blood stream it is possible to induce the cancer cell to internalize the entire complex (receptor-antibody-toxin). Once this occurs, the toxin kills or inactivates the cancer cell, thus preventing it from replicating. The overall result is that the cancer - even if it may not be totally destroyed - stops growing and becomes dormant. It is known that people with dormant cancer cells can lead healthy lives for prolonged periods of time.

The Hebrew University investigators have shown that their method is feasible by introducing a prostate cell carcinoma of human origin adapted to grow in a special strain of immunologically deficient mice (mice which lack an immune system and thus cannot reject the human cells).

When treated with the human antibody-toxin complex, the cancer cells introduced into the mice became dormant, and the mice remained healthy for as long as the treatment continued.

Cancer of the prostate is one of the major cancers of man. Thus, the work conducted by the Lautenberg Center researchers, if shown to be effective in human clinical tests, could be of great practical importance in this and other types of cancer.
-end-
Photo available via e-mail upon request. For further information: Jerry Barach, Dept. of Media Relations, 02-5882904.

The Hebrew University of Jerusalem

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.